NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Radiopharm Theranostics Ltd. RADX
3 fiscal years on record · USD · FY2024 reported · SEC filings only
$-38.3M
Growth
USD 3.6M
Revenue, FY2024 · full 3-year series below
Revenue $M
Net income $M
FY2024 · Revenue 3.6 · Net income -38.3
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−1055 cents
lost on every revenue dollar
Operating margin
Net margin
FY2024 · Operating -1050.6% · Net -1055.3%
ROE
Not available in our data for this period.
The 3-year record
3 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.0 | −0.0 | −0.0 |
| EBITDA $B | · | · | · |
| Income tax $B | 0.0 | 0.0 | 0.0 |
| Net income $B | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | · | · | −0.0 |
| EPS, diluted $ | −1.76 | −12.41 | −11.32 |
| Dividend / sh $ | · | · | · |
| Payout % | · | · | · |
| ROE % | · | · | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 3 failures in 11 reconciliationsAUDITED
No fiscal year had a computed check that closed clean. 84 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente3 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code C3
Fiscal year endsJune 30
SEC categoryemerging growth company
Data on record since2022